Elucidating the function of the exposure of the Bcl-2-BH3 domain on tumor angiogenesis and exploring new Bcl-2-BH4 domain inhibitors to convert the function of Bcl-2 may provide a potential new strategy for anti-angiogenic therapy of breast cancer. This evidence concerns the gene BCL2 and neoplasm.